Research site

London, Greater London WC1N 3JH

2 studies enrolling now · 24 studies all time

What they study most

Acute Ischemic Stroke, Amyotrophic Lateral Sclerosis, Anemia, Breast Cancer, Chronic Kidney Disease, Dialysis-Dependent Chronic Kidney Disease, Hemophilia A, Hypophosphatasia (HPP), Idiopathic Pulmonary Fibrosis, Multiple Sclerosis, Non-Dialysis-Dependent Chronic Kidney Disease, Relapsing Forms of Multiple Sclerosis

Studies at this site

• Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis — Recruiting now
• Registry of Patients With Hypophosphatasia — Enrolling by invitation
• REVEAL-CKD: Prevalence and Consequences of Undiagnosed Chronic Kidney Disease — Completed
• Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS) — Completed
• An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) — Completed
• Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS) — Stopped early
• Plegridy Observational Program — Completed
• Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD) — Completed
• Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease — Completed
• Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) — Completed
• Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) — Stopped early
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis — Completed
• Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B — Completed
• Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A — Completed
• An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis — Stopped early
• Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED) — Stopped early
• International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study — Completed
• Abituzumab in SSc-ILD — Stopped early
• Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke — Completed
• A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis — Stopped early
• Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants — Stopped early
• Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS) — Completed
• Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA) — Stopped early
• Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA) — Stopped early